Advertisement

Clinical Pharmacology of Carboplatin Administered in Alternating Sequence with Paclitaxel in Patients with Non-Small Cell Lung Cancer: A European Cancer Centre (ECC) Study

  • L. J. C. van Warmerdam
  • M. T. Huizing
  • G. Giaccone
  • P. J. M. Bakker
  • J. B. Vermorken
  • P. E. Postmus
  • N. van Zandwijk
  • M. G. J. Koolen
  • W. W. ten Bokkel Huinink
  • R. A. A. Maes
  • W. J. F. van der Vijgh
  • C. H. N. Veenhof
  • J. H. Beijnen

Abstract

The clinical pharmacology of carboplatin, co-administered with paclitaxel, was investigated in a dose-finding and sequence-finding study in 56 previously untreated patients with non-small cell lung cancer (NSCLC). Carboplatin was administered over 30 minutes and paclitaxel over 3 hours every 4 weeks. Patients were randomized for the administration sequence, being first carboplatin (C) then followed by paclitaxel (P) or vice versa. Each patient received the alternate sequence during the second and subsequent courses. Total platinum concentrations in plasma and plasma ultrafiltrate (pUF) were measured applying flameless atomic absorption spectrometry. Ninety-five concentration-time curves were obtained in plasma and pUF.

Paclitaxel doses were initially escalated from P:100 mg/m2+ C:300 mg/m2 with 25 mg/m2 increments to P:225 mg/m2+ C:300 mg/m2. During the course of the study after six dose levels, it became clear that no sequence-depending effect on the toxicity was present, and it was decided to perform the last escalation steps with four patients per dose level. These dose levels were: level 7 (P:225 mg/m2+ C:350 mg/m2), 8 (P:250 mg/m2+ C:350 mg/m2), and 9 (P:225 mg/m2+ C:400 mg/m2). The mean pUF area under the concentration-time curve (AUC) per 300 mg/m2 carboplatin was for the sequence C→P 3.52 (range 1.94–5.83) mg/mL·min, and for the sequence P→C 3.62 (range 1.91–5.01) mg/mL·min, which is not significantly different (p=0.55). Also for other pharmacokinetic parameters no sequence depending effect was observed. Non-hematological toxicities consisted mainly of myalgia and bone pain. The most important hematologic toxicity was neutropenia, without, interestingly, any thrombocytopenic periods. The AUCs of carboplatin were probably too low to induce thrombocytopenia, although antagonistic properties of paclitaxel cannot be excluded.

Keywords

Clin Oncol Mean Residence Time Alternate Sequence Administration Sequence Paclitaxel Dose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wagstaff AJ, Ward A, Benfield P, et al: Carboplatin, a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 37: 162 (1989).CrossRefPubMedGoogle Scholar
  2. 2.
    Vermorken JB, ten Bokkel Huinink WW, Eisenhower EA, et al: Carboplatin versus cisplatin. Ann Oncol 4: S41 (1993)CrossRefGoogle Scholar
  3. 3.
    Jodrell DI, Egorin MJ, Canetta RM, et al: Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10: 520 (1992)PubMedGoogle Scholar
  4. 4.
    Gatzemeier U, Heckmayr M, Hossfeld DK, et al. Phase II study of carboplatin in untreated inoperable non-small cell lung cancer. Cancer Chemother Pharmacol 26: 369 (1990)CrossRefPubMedGoogle Scholar
  5. 5.
    Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the eastern cooperative oncology group. J Clin Oncol 7: 1602 (1989)PubMedGoogle Scholar
  6. 6.
    Spencer CM, Faulds D. Paclitaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatments of cancer. Drugs 48: 794 (1994)CrossRefPubMedGoogle Scholar
  7. 7.
    Rowinsky EK. Clinical pharmacology of taxol. J Natl Cancer Inst 15: 25 (1993)Google Scholar
  8. 8.
    Huizing MT, Keung ACF, Rosing H, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11: 2127 (1993).PubMedGoogle Scholar
  9. 9.
    Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 85; 384 (1993).CrossRefPubMedGoogle Scholar
  10. 10.
    Chang AY, Kim K, Glick J, et al. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: the eastern cooperative oncology group results. J Natl Cancer Inst 85: 388 (1993)CrossRefPubMedGoogle Scholar
  11. 11.
    Ettinger DS. Taxol in the treatment of lung cancer. Mongraphs Natl Cancer Inst 15: 177 (1993)Google Scholar
  12. 12.
    Parker RJ, Dabholkar MD, Lee KB, et al. Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. J Natl Cancer Inst 15: 83 (1993)Google Scholar
  13. 13.
    Liebmann JE, Fisher J, Teague D, Cook JA. Sequence dependence of paclitaxel (taxol) combined with cisplatin or alkylators in human cancer cells. Oncol Res 6: 25 (1994)PubMedGoogle Scholar
  14. 14.
    Rowinsky EK, Citardi MJ, Noe DA, et al. Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol 119: 727 (1993)CrossRefPubMedGoogle Scholar
  15. 15.
    Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequence of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9: 1692 (1991)PubMedGoogle Scholar
  16. 16.
    Beijnen JH, Bais EM, Ten Bokkel Huinink WW. Lithium pharmacokinetics during cisplatin-based chemotherapy: a case report. Cancer Chemother Pharmacol 33: 523 (1994)CrossRefPubMedGoogle Scholar
  17. 17.
    Grossman SA, Sheidler VR, Gilbert MR. Decreased phenytoin levels in patients receiving chemotherapy. Am J Med 87: 505 (1989)CrossRefPubMedGoogle Scholar
  18. 18.
    Neef C, De Voogd-van der Straaten I. An interaction between cytostatic and anticonvulsant drugs. Clin Pharmacol Ther 43: 372 (1988)CrossRefPubMedGoogle Scholar
  19. 19.
    Balis FM. Pharmacokinetic drug interactions of commonly used anticancer drugs. Clin Pharmacokinet 11: 223 (1986)CrossRefPubMedGoogle Scholar
  20. 20.
    Schellens JHM, Ma J, Brumo R, et al. Pharmacokinetics of cisplatin and taxotere and WBC DNA-adduct formation of cisplatin in the sequence taxotere/ cisplatin and cisplatin/ taxotere in a phase I/II study in solid tumor patients. Proc Am Soc Clin Oncol 13: 132 (1994)Google Scholar
  21. 21.
    Relling MV, McLeod HL, Bowman LC, Santana VM. Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Clin Pharmacol Ther 56: 503 (1994)CrossRefPubMedGoogle Scholar
  22. 22.
    Rowinsky E, Grochow L, Kaufmann S, et al. Sequence-dependent effect of topotecan and cisplatin in a phase I and pharmacologic study. Proc Am Soc Clin Oncol 13: 142 (1994)Google Scholar
  23. 23.
    Van der Vijgh WJF: Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 21: 242 (1991)CrossRefPubMedGoogle Scholar
  24. 24.
    Saikawa Y, Kubota T, Kuo TH, et al. Combined effect of 5-fluorouracil and carboplatin against human gastric cancer cell lines in vitro and in vivo. Anticancer Res 14: 461 (1994)PubMedGoogle Scholar
  25. 25.
    Dofferhof ASM, Berendsen HH, Van de Naalt J, et al. Decreased phenytoin level after carboplatin treatment. Am J Med 89: 247 (1990)CrossRefGoogle Scholar
  26. 26.
    Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748 (1989)PubMedGoogle Scholar
  27. 27.
    Egorin MJ, Van Echo DA, Tipping SJ, et al. Pharmacokinetics and dosage reduction of cis-diammine (1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer Res 44: 5432 (1984)PubMedGoogle Scholar
  28. 28.
    Marina NM, Rodman J, Shema S, et al. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. J Clin Oncol 11: 554 (1993)PubMedGoogle Scholar
  29. 29.
    Reyno LM, Egorin MJ, Canetta RM, et al: Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J Clin Oncol 11: 1156 (1993)PubMedGoogle Scholar
  30. 30.
    Proost JH, Meijer DKF. MW/PHARM, An integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 22: 155 (1992)CrossRefPubMedGoogle Scholar
  31. 31.
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 16: 31 (1976)CrossRefPubMedGoogle Scholar
  32. 32.
    Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9: 503 (1981)CrossRefPubMedGoogle Scholar
  33. 33.
    Van Warmerdam LJC, Ten Bokkel Huinink WW, Maes RAA, et al. Limited-sampling models for anticancer agents. J Cancer Res Clin Oncol 120: 427 (1994)CrossRefPubMedGoogle Scholar
  34. 34.
    LeBlanc GA, Sundseth SS, Weber GF, et al. Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res 54: 540 (1992)Google Scholar
  35. 35.
    Vadhan-Raj S, Kudelka AP, Garrison L, Gano J, Edwards CL, Freedman RS, Kavanagh JJ. Effects of interleukin-1α on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. J Clin Oncol 12: 707 (1994)PubMedGoogle Scholar
  36. 36.
    Langer CJ, Leighton J, Comis R, McAleer C, et al. Taxol and carboplatin in combination in stage IV and IIIB non-small cell lung cancer: a phase II trial. Proc Am Soc Clin Oncol 13: 338 (1994)Google Scholar
  37. 37.
    Israel VK, Zaretsky S, Natale RB. Phase I/II trial of combination carboplatin and taxol in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 13: 351 (1994)Google Scholar
  38. 38.
    Paul DM, Johnson DH, Hande KR, et al. Carboplatin and taxol: a well tolerated regimen for advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 13: 352 (1994)Google Scholar
  39. 39.
    Shea T, Graham M, Steagall S, et al. Multiple cycles of high dose taxol plus carboplatin with G-CSF (filastrim) and peripheral blood progenitor support. Proc Am Soc Clin Oncol 13: 150 (1994)Google Scholar
  40. 40.
    Van Warmerdam LJC, Ten Bokkel Huinink WW, Beijnen JH. Overwegingen voor het gebruik van de Calvert-formule bij het doseren van carboplatine. Pharm Weekbl 128: 749 (1993)Google Scholar
  41. 41.
    Pluznik DH, Lee NS, Sawada T. Taxol induces the hematopoetic growth factor granulocyte-macrophage colony-stimulating factor in murine B-cells by stabilization of granulocyte-macrophage colony-stimulating factor nuclear RNA. Cancer Res 54: 4150 (1994)PubMedGoogle Scholar
  42. 42.
    Viallet J, Boucher L, Gallant G. In vitro interactions between paclitaxel and other agents in human non small cell lung cancer lines: antagonism with etoposide and doxorubicin. Proc Am Soc Clin Oncol 13: 365 (1994)Google Scholar
  43. 43.
    Ten Bokkel Huinink WW, Veenhof CHN, et al. Carboplatin and paclitaxel in patients with advanced ovarian cancer, a dose finding study. Ann Oncol 5: 99 (1994)Google Scholar
  44. 44.
    Ozols RF, Kilpatrick D, O’Dwyer P, et al. Phase I and pharmacokinetic study of taxol (T) and carboplatin (C) in previously untreated patients (pts) with advanced epithelial ovarian cancer (oc): a pilot study of the gynaecologic oncology group. Proc Am Soc Clin Oncol 12: 259 (1993)Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • L. J. C. van Warmerdam
  • M. T. Huizing
  • G. Giaccone
  • P. J. M. Bakker
  • J. B. Vermorken
  • P. E. Postmus
  • N. van Zandwijk
  • M. G. J. Koolen
  • W. W. ten Bokkel Huinink
  • R. A. A. Maes
  • W. J. F. van der Vijgh
  • C. H. N. Veenhof
  • J. H. Beijnen
    • 1
  1. 1.Dept of PharmacyNetherlands Cancer Institute/Antoni van Leeuwenhoek Hospital and Slotervaart HospitalAmsterdamThe Netherlands

Personalised recommendations